The FORCE Blog
Our blog features information and personal perspectives on topics of interest to the hereditary cancer community.

Stay up to date on research and information

Sign Up for FORCE Newsletters
Education > Our Blog > FORCE Co-Authors Paper on Engaging Patient Advocates in Research

Your information is used for the sole purpose of sending information about hereditary cancer and updates on FORCE programs and campaigns. To stop receiving these updates, click unsubscribe at the bottom of any email. If you need additional support, or have any questions, please contact [email protected].

FORCE Co-Authors Paper on Engaging Patient Advocates in Research

August 27, 2018

FORCE Co-Authors Paper on Engaging Patient Advocates in Research

by Lisa Schlager

A year ago, I wrote a blog titled “Working with Industry to Increase Patient Engagement in Drug Development.”  In it, I shared that FORCE is a member of Bayer Pharmaceutical’s 5-member Patient Advocacy Advisory Council (PAAC), a novel partnership between this leading drug developer and the patient advocate community. From late 2016 through early this year, we worked with our PAAC partners and Bayer to develop a framework for successful integration of patient experts into its clinical trials.

A significant part of that framework was development of a Bayer-specific patient advocate training platform and criteria for engaging capable patient representatives. We are delighted that Kate Robins, a BRCA+ ovarian cancer survivor and FRAT graduate, served as Bayer’s first patient expert. Kate helped lay the foundation for incorporation of the patient perspective in every facet of the company’s clinical research and drug development programs.

While the concept of patient-focused drug development (PFDD) is not completely novel, successful implementation can present challenges because it requires a shift in priorities and practices for industry partners and researchers. FORCE is proud of the work we are doing to establish best practices to guide successful patient involvement in research—not only as a participant, but as an integral team member in guiding the questions studied, how the research is conducted, methods of disseminating results, etc.  

As a founding member of the PAAC, FORCE took part in writing a white paper on the lessons learned from this project. We are pleased that the manuscript was recently published in Therapeutic Innovation & Regulatory Science (TIRS), the official scientific journal of the Drug Industry Association (DIA) which strives to advance medical product discovery, development, regulation, and use. We are honored to represent the hereditary patient community and will continue our efforts to ensure that the voice of the patient is always front and center.

FORCE's Research Advocate Training Program (FRAT) provides a path for volunteers to represent the hereditary cancer community in research. You can apply for this free, online training by completing our volunteer application

Read the article.

Posted in: Research
Tags: Clinical Trials , Patient Advocacy , Patient Engagement , Cancer Research , Research Advocacy , Patient Centered Research


November 15, 2018

Eva May says:
Congratulations to Bayer for recognizing the value of patient advocates in clinical trial development and implementation and to FORCE for making it happen! Unfortunately we cannot get access to the article without a subscription. Can you give readers a link to a public access version? Thanks!


Leave a Reply